Here are some important highlights from the meeting.
Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., and Actelion.
 

 

Transbronchial Cryobiopsy for the Diagnosis of ILD
— Dr. Paul W. Noble

Fleischner Society Update in Classification of IPF
— Dr. David A. Lynch

 


ICD-10 Codes and Nomenclature for Classification of PAH
— Dr. Ronald J. Oudiz

NTM and Treatment Strategies for Patients with Cavitary Disease
— Dr. Sandra G. Adams

 


Real World Experience in Patients with COPD
— Dr. Sandra G. Adams

Palliative Care for Patients with IPF
— Dr. Meena Kalluri

 

 


New Developments in the Diagnosis and Management of IPF
— Dr. Anoop M. Nambiar

Registry Data Provide Important Severity Indicators for PH
— Dr. Ronald J. Oudiz

 


The Latest in IPF: Implications for Clinical Practice
— Drs. Lisa H. Lancaster &  Maria L. Padilla

Perspectives on Side Effect Management
— Drs. Lisa H. Lancaster &  Maria L. Padilla

 


IPF Management Considerations
— Drs. Lisa H. Lancaster &  Maria L. Padilla

Questions for the experts | Transcript

 

 

 

 

 


Conference Coverage Q&A

 
 nathan  

Take advantage of this unique opportunity to have your clinical questions addressed by expert faculty. Your questions will be answered by email within 2 weeks.

Continue


Dr. Lynch discussed the new Fleischner Society diagnostic criteria for IPF. What are the new diagnostic categories of usual interstitial pneumonia (UIP), based on CT patterns?

Ask the Expert  

The following table includes the distribution and features associated with the 4 different diagnostic categories of UIP based on CT patterns from the new Fleischner Society guidelines.

Lynch DA, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med. 2018;6:138-153. https://www.ncbi.nlm.nih.gov/pubmed/29154106




Dr. Nambiar said that combination studies with pirfenidone and nintedanib have shown that treatment with the antifibrotic agents combined is well tolerated. What were the most common adverse events, and is there any information yet on the efficacy of combination treatment?

Ask the Expert  

Vancheri et al have recently published results from an open-label trial of nintedanib with add-on pirfenidone in patients with IPF (the INJOURNEY Trial). In this study, patients with IPF and FVC ≥50% predicted at screening who completed a 4–5 week run-in with nintedanib 150 mg bid without dose reduction or treatment interruption were randomized to nintedanib 150 mg bid with add-on pirfenidone (titrated to 801 mg tid) (n = 53), or nintedanib 150 mg bid alone (n = 52), open-label for 12 weeks. The primary endpoint was the percentage of patients with on-treatment gastrointestinal adverse events from baseline to week 12. Analyses were descriptive and exploratory. GI AEs were reported for 69.8% of patients treated with nintedanib with add-on pirfenidone and in 52.9% of patients treated with nintedanib alone. Diarrhea, nausea and vomiting were the most frequent AEs, occurring in 37.7%, 41.5% and 28.3% respectively, with combination treatment, compared with 31.4%, 11.8%, and 11.8% with nintedanib treatment alone. At 12 weeks, the mean absolute change from baseline in FVC was -13.3±17.4 mL in the nintedanib + pirfenidone group compared with -40.9 ± 31.4 mL for nintedanib treatment alone.

Vancheri C, et al. Am J Respir Crit Care Med. 2017 Sep 10. [Epub ahead of print] Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis: Results of the INJOURNEY Trial. Available at https://www.ncbi.nlm.nih.gov/pubmed/28889759. Accessed November 30, 2017.

An open-label, single arm, 24 week safety and tolerability study of pirfenidone in combination with nintedanib has also been conducted in patients with IPF (NCT02598193), however the results of this study have not been published to date.




Here are some important highlights from the meeting.
Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
 

 

New Research on Mechanisms in the Development of PF
— Dr. Sonye K. Danoff

Exploring New Therapeutic Avenues for Managing PF
— Dr. Sonye K. Danoff

 


New Approaches to the Diagnosis of IPF
— Dr. Timothy P. Whelan

Updates on Registry Enrollment and Growth of the Care Center Network
— Dr. Timothy P. Whelan

 


Exploring the Basic Mechanisms that Contribute to Development of Lung Fibrosis
— Drs. Danoff and Whelan

Transcript

Gene Abnormalities and ILD
— Drs. Danoff and Whelan
 

Transcript

 


Environmental Influences on the Development of Pulmonary Fibrosis
— Drs. Danoff and Whelan

Genetics and Personalized Medicine for Patients with Pulmonary Fibrosis
— Drs. Danoff and Whelan

 

 


Independent Conference Coverage from the CHEST 2018 Annual Meeting*
Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., and Actelion.

 

Take Home Messages from the 2018 CHEST Annual Meeting

Evolution of Antifibrotic Therapy in IPF

 

 


Overview of the Latest Clinical Trials in IPF

Updates in the Diagnosis of ILD and the Role of Cryobiopsy

 



Management of IPF Patients in 2018

Comparing the 2017 Fleischner Society Guidelines and the 2018 ATS Guidelines for Diagnosing IPF

 


What We’re Learning from the IPF-PRO Registry

The Importance of Early Integration of Palliative Care

 


Updates in Inoperable CTEPH

Download Audio


*This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings of the 2018 CHEST Annual Meeting.
 

Conference Coverage Q&A

Do you Have a Question?

Ask an Expert >>

 

Check out recently submitted questions:

View >>